News

Opioid prescription decreased substantially in 2 years following 2016 CDC guideline for prescribing opioids for chronic pain.

Baseline eGFR and increasing age were good predictors of eGFR.

Sustained virologic response following direct acting antiviral treatment substantially reduced the all-cause mortality rate in patients with HCV.

The rate of major thromboembolism within 90 days was 1.2% for placebo and 1.0% for dalteparin.

A new Polish study calls for greater focus on asthma and the link to delirium in older patients, who may face greater mortality risk.

More than half of the patients in the study were treated for inflammatory bowel disease with infliximab.

A large number of nationwide infection rates in long-term care facilities are a product of seasonal influenza and RSV, according to a new study.

Researchers urge parents and doctors to take a closer look at the common disease and its possible more severe subtypes.

The expansion for sofosbuvir/velpatasvir is supported by phase 2 data showing an 83% sustained virologic response or cure rate among patients as young as 3 years old.

Patients included in the study had a median of 3 prior CDI episodes and 4 risk factors for recurrent infections.

Reported HRQOL remains consistent in youth with T1D, but multiple comorbidities and mental health conditions linked to decline.

Dapagliflozin and the SGLT2 inhibitor class may have untapped potential far beyond the reduction of heart failure hospitalization risk.

REL-1017 was more effective when administered earlier rather than later.

A systematic review of clinical trials notes that topical eye drops may lead to favorable retinal and visual outcomes, despite heterogeneity across multiple studies.

Data show 21.2% of patients with CAD reported angina at least once monthly, with 12.5% reporting daily or weekly angina.

Elexacaftor/tezacaftor/ivacaftor and ivacaftor was previously approved for CF patients at least 12 years old.

The UNITI studies have shown ustekinumab is effective at inducing and maintaining clinical remission in Crohn’s disease patients.

The COVID-19 pandemic had forced vitiligo patients to delay treatments; however, not much is known about the effects of delaying on disease course.

An expert discussion on the recent FDA committee decision to support teplizumab in delaying clinical type 1 diabetes.

The approval for Biogen’s disease-modifying, anti-amyloid agent aducanumab follows a long regulatory journey.

Using both tests to screen for colorectal cancer was more effective than just using colonoscopies alone.

COVID-19 severity should be looked at in the context of pre-existing comorbidities, age, social determinants, and bias among data sources.

Potential public health benefit of OAT linked to 50% lower risk of all-cause mortality.

The higher levels of visits were mostly maintained throughout the pandemic.

Direct-acting antivirals has increased the need to treat children HCV patients before they begin to engage in dangerous behaviors.

The US is expected to fall just short of the goal of having 70% of adults vaccinated by July 4.

The new indication for the therapy provides coverage for patients with the rare blood disease as young as 1 month old.

Misha Rosenbach, MD, gives an overview of climate change and its relevance to dermatology.